Previous Article | Next Article ![]()
Journal of Clinical Microbiology, February 2000, p. 800-806, Vol. 38, No. 2
Department of Infectious Diseases
Epidemiology,1 Diagnostic Laboratory for
Infectious Diseases and Perinatal Screening,3
and Laboratory for Clinical Vaccine
Research,4 National Institute of Public
Health and the Environment, Bilthoven, Department of Pediatrics,
`Groene Hart' Hospital, Gouda,2 and
Laboratory of Medical Microbiology, St. Elisabeth Hospital,
Tilburg,5 The Netherlands
Received 16 July 1999/Returned for modification 28 September
1999/Accepted 1 November 1999
Laboratory confirmation of pertussis by culture, PCR, or detection
of antibody increase in paired sera is hampered by low sensitivity in
the later stages of the disease. Therefore, we investigated whether,
and at which level, concentrations of immunoglobulin G (IgG) antibodies
against pertussis toxin (PT), IgG-PT, in a single serum
sample are indicative of active or recent pertussis. IgG-PT, measured
by enzyme-linked immunosorbent assay in units per milliliter,
was analyzed in 7,756 sera collected in a population-based study in The
Netherlands, in the sera of 3,491 patients with at least a fourfold
increase of IgG-PT, in paired sera of 89 patients with
positive cultures and/or PCR results, and in the sera of 57 patients with clinically documented pertussis with a median follow-up
of 1.4 years. We conclude that, independently of age, IgG-PT levels of
at least 100 U/ml are diagnostic of recent or active
infection with Bordetella pertussis. Such levels are
present in less than 1% of the population and are
reached in most pertussis patients within 4 weeks after disease onset
and persist only temporarily.
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Specificity and Sensitivity of High Levels of Immunoglobulin G
Antibodies against Pertussis Toxin in a Single Serum Sample for
Diagnosis of Infection with Bordetella pertussis
*
Corresponding author. Mailing address: Diagnostic
Laboratory for Infectious Diseases and Perinatal Screening,
National Institute of Public Health and the Environment, P.O. Box
1, 3720 BA Bilthoven, The Netherlands. Phone: 31-30-274-2190. Fax:
31-30-274-4418. E-mail: j.schellekens{at}rivm.nl.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|